Eligible patients were males (any age) with severe or moderately severe hemophilia A with FVIII ≤2% receiving on-demand FVIII at the time of study enrolment and who had >50 previous exposure days (EDs) to any recombinant or plasma-derived FVIII, a negative inhibitor result at screening (defined as <0.6 Bethesda units/mL [BU/mL]), and no history of inhibitor development. Patients were discontinued from the study if they required a surgical or dental procedure.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.